Engineering safer neuropsychiatric compounds

Safety
Achieved
Through
Engineering.

We design molecules and therapies to improve clinical efficacy while reducing physical and psychological risks

Our
Pipeline

Arcadia Medicine is advancing a pipeline of promising therapeutic candidates designed to address mental health disorders that were previously intractable or inadequately addressed with existing therapeutics

Drug

In Development

Preclinical

Phase I/II

Phase III

AM-1002

PTSD
(Post-Traumatic Stress Disorder)

AM-1002 is a phenethylamine empathogen which has been optimized for use in drug-assisted psychotherapy for patients suffering from PTSD. AM-1002’s composition has been optimized to produce a shorter time course and safer non-neurotoxic drug profile, as compared to MDMA.

AM-1004

MDD
(Major Depressive Disorder)

AM-1004 is a combination (psychoactive-empathogen) product designed for the treatment of major depression. Its profile has been generated to produce fewer negative psychological and physical side effects compared to psilocybin therapy and to have a shorter time course.

AM-1006

SA
(Substance Abuse)

AM-1006 is an internasal low-dose psychoactive product which has been designed to produce a short acting effect for optimized use in a traditional hour-long therapeutic setting.

Our
Pipeline

PRECLINICAL

AM-1002

PTSD (Post-Traumatic Stress Disorder)

AM-1002’s composition has been optimized to produce a shorter time course and safer non-neurotoxic drug profile, as compared to MDMA.

IN DEVELOPMENT

AM-1004

MDD (Major Depressive Disorder)

IN DEVELOPMENT

AM-1006

SA (Substance Abuse)

AM-1006 is an internasal low-dose psychoactive product which has been designed to produce a short acting effect for optimized use in a traditional hour-long therapeutic setting.

Discovery Platform

Predict

Arcadia’s computational generative model identifies psychoactive candidates of interest by identifying an optimal drug pharmacology and profile based on a large assortment of data and relevant safety parameters.

Select

Top candidates and combinations are identified and evaluated based on their pharmacology, pharmacokinetics, and half-life to ensure a safe and effective drug profile.

Learn

Our process continuously generates large datasets, which is used to continuously curate and improve the prediction process before and during the clinical evaluation process.